Disclaimer Forward-Looking Statements This presentation contains forward looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activi

PYNNACLE Phase 2 Clinical Data Update

Investor Webinar September 10, 2025 Exhibit 99.1

Disclaimer Forward-Looking Statements

This presentation contains forward looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for rezatapopt, including the

timing of disclosures regarding clinical data updates of its current clinical trial for rezatapopt, expected therapeutic benefits of rezatapopt including potential efficacy and tolerability, plans regarding regulatory filings and approvals,

including targeted dates for our NDA submission and initial FDA approval for platinum-resistant or refractory ovarian indication, ongoing safety and response rate of participants in our PYNNACLE study, as well as the overall timing and success of

our current and future clinical trials for rezatapopt, and the adequacy of the data to support its regulatory approval, and our expectations regarding the therapeutic, addressable patient populations, timing for approval and commercial potential of

rezatapopt, as well as our cash runway forecast. The words "believe," "may," "should," "will," "estimate," "promise," "plan", "continue,"

"anticipate," "intend," "expect," "potential" and similar expressions (including the negative thereof), are intended to identify forward-looking statements. Because such statements are subject to risks

and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: our preclinical studies and clinical

trials may not be successful; the U.S. Food and Drug Administration (FDA) may not agree with our interpretation of the data from clinical trials of our product candidates; we may decide, or the FDA may require us, to conduct additional clinical

trials or to modify our ongoing clinical trials, which could result in enrollment or other delays to our anticipated timelines; we may experience delays in the commencement, enrollment, completion or analysis of clinical testing for our product

candidates, or significant issues regarding the adequacy of our clinical trial designs or the execution of our clinical trials may arise, which could result in increased costs and delays, or limit our ability to obtain regulatory approval; the

commencement, enrollment and completion of clinical trials and the reporting of data; a global pandemic, other public health emergencies or geopolitical tensions or conflicts may disrupt our business and that of the third parties on which we depend,

including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity; our product candidates may not receive regulatory approval or be successfully commercialized;

unexpected adverse side effects or inadequate therapeutic efficacy of our product candidates could delay or prevent regulatory approval or commercialization; we may not be able to obtain additional financing on terms acceptable to us or at all; as

well as those risks and uncertainties set forth in the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Annual Report on Form 10-K, filed

with the Securities and Exchange Commission (the "SEC") on March 3, 2025, the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2025, filed with the SEC on May 9, 2025, and the Company's Quarterly

Report on Form 10-Q for the three months ended June 30, 2025, filed with the SEC on August 7, 2025, and its other filings filed with the SEC.. Additional risks and uncertainties may emerge from time to time, and it is not possible for PMV

Pharma's management to predict all risk factors and uncertainties. All forward-looking statements contained in this presentation speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect

events that occur or circumstances that exist after the date on which they were made. This presentation does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state

or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Today's Objectives Rezatapopt

background Ovarian cancer treatment landscape PYNNACLE Phase 2 interim data update Initial NDA strategy informed by FDA feedback Q&A 01 02 03 04 David Mack, PhD President and Chief Executive Officer Ramez N. Eskander, MD Professor, Department of

Obstetrics, Gynecology, and Reproductive Sciences UC San Diego Deepika Jalota, PharmD Chief Development Officer Panel

Today's Objectives Rezatapopt

background Ovarian cancer treatment landscape PYNNACLE Phase 2 interim data update Initial NDA strategy informed by FDA feedback Q&A 01 02 03 04 David Mack, PhD President and Chief Executive Officer

PMV's lead candidate is

rezatapopt, a first-in-class, investigational p53 Y220C reactivator The p53 Y220C mutation, a previously undruggable target, is found in 2.9% of ovarian cancer and 1% of all solid tumors Phase 1 PYNNACLE study has achieved proof of concept data for

rezatapopt Pivotal Phase 2 PYNNACLE study interim clinical data demonstrates favorable efficacy and safety across multiple tumor types Strong balance sheet with $148M as of June 30, 2025, with cash runway through 1Q2027 NDA submission planned

in 1Q2027 in platinum-resistant/refractory ovarian cancer patients PMV Pharma is Harnessing the Power of p53 to Treat Cancer

Rezatapopt Targets TP53 Y220C Hotspot

Mutation Detected Across Solid Tumors TP53 mutations are the most common genomic alterations across all human cancers1 Most TP53 mutations occur in the central DNA-binding domain and ten of them are referred to as hot-spot' mutations,

accounting for ~30% of the TP53 mutations observed in human cancer1-2 p53 Y220C is a key hot-spot TP53 missense mutation that destabilizes p531,3 p53 Y220C present in ~1% of solid tumors4 Addressable 2L+ U.S. & EU4/UK patients ~12K4,5

Deoxyribonucleic acid. 1 Baugh EH, et al. Cell Death Differ. 2018;25,154-160. 2 Roszkowska KA, et al. Int J Mol Sci. 2020;21:1334. 3 Bouaoun L, et al. Hum Mutat. 2016;37:865-876. 4 Foundation Insights, Schram et al. AACR-NCI-EORTC

Conference 2023. 5 DRG Epidemiology Estimates 2028. Frequency of TP53 Y220C Across Common Solid Tumors Foundation Medicine Tissue and Heme assay test results collected between 1/1/2012 and 5/31/2024 The prevalence of TP53 Y220C across different

diseases was analyzed by using the FoundationInsights web-based software platform to query a pan-solid tumor cohort of ~367,651 US-based, consented-for-research patients in the FoundationCore Database4 that received FMI's

Commercial Tissue or Heme assays between 1/1/2012 and 5/31/2024. Ovarian 2.9% Breast 1% Lung 1% Endometrial 1.2%

Rezatapopt is a p53 Y220C-Selective

First-in-Class p53 Reactivator Orally available small molecule designed to selectively bind to the pocket contained in the p53 Y220C mutant protein1 Stabilizes the p53 Y220C mutant protein in the wild-type p53 conformation, thereby restoring

transcription and tumor-suppressor function1 Inhibits proliferation across all Y220C-expressing cell lines p53 Y220C PC14586 Tumor regression in vivo 0 Days Tumor volume (mm3) 5 10 15 20 25 0 500 1000 1500 2000 2500 Vehicle, QDx21 PC14586, 25

mg/kg, QDx21 PC14586, 50 mg/kg, QDx21 PC14586, 100 mg/kg, QDx21 PC14586 ( M) P21 or MDM2/GAPDH 0.01 0.1 1 10 0 20 40 60 NUGC-3 (Y220C) NUGC-3_KO (KO) SJSA-1 (WT) HCT 116 (WT) A-431 (R273H) C-33 A (R273C) TOV-112D (R175H) NCI-H2029 (Y220D)

SU.86.86 (G245S) SF-295 (R248Q) EFE-184 (R282W) p21 MDM2 p53 transcriptional activity restored Stabilizes p53 Y220C mutant in the WT p53 conformation PC14586 = rezatapopt NUGC-3 model MDM2, mouse double minute 2 homolog; KO, knockout; WT, wild-type.

1Dumble M, et al. Cancer Res. 2021;81(13_Suppl):Abstract LB006. NUGC-3: gastric cancer cell line

4Q2020 1Q2024 2025 PYNNACLE Phase 1

first patient enrolled FDA alignment on RP2D and Phase 2 pivotal trial design Pivotal Phase 2 trial first patient enrolled Phase 2 interim clinical data Received FDA feedback on NDA submission strategy to support a PROC indication Phase 2 interim

clinical data support initial NDA submission strategy for PROC indication Phase 1 established RP2D as rezatapopt 2000mg once daily with food Early efficacy signals and well-tolerated safety profile across multiple tumor types Seamless Phase 1/2

PYNNACLE Clinical Trial: Rapid Rezatapopt Monotherapy Development Towards NDA Submission RP2D, recommended Phase 2 dose; FDA, Food and Drug Administration; PROC, platinum-resistant/refractory ovarian cancer; NDA, New Drug Application

Compelling Rezatapopt Monotherapy

Phase 2 Interim Data 1 Natural history study (PMV data on file); ORR, overall response rate; FDA, Food and Drug Administration Across All Cohorts: Encouraging efficacy in heavily pre-treated patients with a TP53 Y220C mutation with poor prognoses1

Promising rate of tumor responses observed across multiple tumor types ORR: 33% Median duration of response: 6.2 months Differentiated safety and tolerability profile compared to standard of care Ovarian Cancer: Significant unmet medical need Strong

response rate and benefit ORR: 43% Median duration of response: 7.6 months Initial registrational opportunity in platinum-resistant or refractory ovarian cancer (PROC) informed by FDA feedback TP53 Y220C mutation leads to a worse prognosis1 Emerging

clinical data supports rezatapopt as an effective, well-tolerated, oral option Opportunity to deliver a novel, biomarker-selected chemo-alternative

Today's Objectives Rezatapopt

background Ovarian cancer treatment landscape PYNNACLE Phase 2 interim data update Initial NDA strategy informed by FDA feedback Q&A 01 02 03 04 Ramez N. Eskander, MD Professor, Department of Obstetrics, Gynecology, and Reproductive Sciences UC

Disclosures Consultant/Advisory

Board: AstraZeneca Clovis Oncology Daiichi Sankyo, Inc. Eisai Inc. Elevar Therapeutics GSK ImmunoGen, Inc. Mersana Therapeutics Myriad Genetics, Inc. Novocure GmbH Onconova Therapeutics Nuvectis PMV Pharmaceuticals Regeneron Lilly AbbVie Pfizer

Other Financial or Material Support for GOG Associate Clinical Trial Advisor

Ovarian Cancer is a Leading Cause

of Cancer Death Among Women a mOS in patients with recurrent PSOC can vary widely based on time since last platinum-based chemotherapy / length of time to recurrence, stage at initial diagnosis, and the presence of specific mutations. mOS, median

overall survival. Full citations for footnotes 1-10 are provided in the References slide. Estimated new US cases in 2025: 20,8901,2 Estimated deaths in 2025: 12,7301,2 5-year relative survival: 51.6%1,2 5-year relative survival: ~30% for distant

metastasis2 Up to 80% with advanced disease will relapse within 12-18 months3,5-9 >70% present with advanced disease2 Platinum-sensitive: mOS 4 yearsa,3,4,10 Platinum-resistant: mOS <1 year3,4,8-10 Recurrent ovarian

cancer 5-year survival rate: <30%5

TP53 Mutations are Present in

>75% of Ovarian Cancer Cases and are Associated with Poor Prognosis TP53 mutations Mutated p5316,17 High frequency in more aggressive and invasive tumor subtypes15,19-22 a The prevalence of TP53 Y220C was assessed in a cancer tumor cohort

of 598,012 US-based, consented-for-research patients using FoundationInsights (May 2024). 15 HGSOC, high-grade serous ovarian carcinoma; MMR, mismatch repair; WT, wildtype. Full citations for footnotes 11-15, 19-30 are provided in the

References slide. TP53 mutations and prognosis Retrospective studies TP53 mutation: Negative prognostic indicator of survival and outcomes across several tumor types, including ovarian cancer22-30 c HGSOC accounts for 70-75% of

epithelial ovarian cancer cases11-14 Most common subtype, often diagnosed at advanced stages11-14 c In >75% of ovarian cancers15,a In >95% of HGSOC cases15,a TP53 dysfunction in fallopian tubal cells initiates HGSOC13,16

The Benefit of Treatment Decreases

with Multiple Lines of Therapy9, 31-52 mPFS 16-21 months mPFS 5-14 months Tumour volume expressed in CA-125 level (MU/mL) Disease-free survival (months) Ileus SYMPTOMS 4+ months SURGERY DISEASE RELAPSE Second-line platinum

chemotherapy bevacizumab Third-line platinum chemotherapy Non-platinum chemotherapy First-line chemotherapy bevacizumab maintenance PARPi maintenancea * 1ST LINE 5TH LINE 2ND LINE 3RD LINE 4TH LINE a Niraparib should only be

used in patients with an HRD+ status. CA-125,cancer antigen 125; HRD+, homologous recombination deficiency-positive status; mPFS, median progression-free survival; PARPi, PARP inhibitor; SOC, standard of care. Slide courtesy of and adapted from

Kathleen Moore. References 9,31-52. Full citations for footnotes 9, 31-52 are provided in the References slide.

Single agent chemotherapy

(non-platinum) +/- Concurrent bevacizumab Mirvetuximab soravtansine Clinical Trial Carboplatin doublet +/- Concurrent bevacizumab +/- PARP inhibitor maintenance Patients will Eventually Develop PROC Reflecting a High Unmet Medical Need53-54

Initial therapy Recurrence Platinum-sensitive (relapse >6 months) Platinum-resistant (relapse 6 months) Recurrent PROC continues to have a devastating prognosis Full citations for footnotes 53-54 are provided in the References slide.

Surgery Staging Debulking Systemic therapy Carboplatin + paclitaxel +/- concurrent bevacizumab +/- PARP inhibitor maintenance

ORR (%) Adding Bevacizumab to

Chemotherapy has Provided Benefit in PROC AURELIA Phase 369 (N=358) CT + BEV vs CT ORR: 27.3% vs 11.8% mPFS: 6.7 vs 3.4 mo mOS: 16.6 vs 13.3 mo P=0.001 FDA approved for PROC Nov 2014 CT n=182 BEV + CT n=179 BEV, bevacizumab; CT, chemotherapy; CI,

confidence interval; mPFS, median progression-free survival; mo, months; mOS, median overall survival; ORR, overall response rate; PROC, platinum-resistant ovarian cancer. Full citations for footnote 69 is provided in the References slide.

30-40% of patients with PROC

are FR -positive ( 75% cells with 2+ intensity staining)56-59 c Mirvetuximab Soravtansine (ADC) is Approved for FR -Positive PROC MIRV (n=227) CT (n=226) 42.3% 15.9% ORR (%) 26.4% 95% CI: 18.4-34.4 P<0.001

MIRASOL Phase 3 (N=453)56 Mirvetuximab soravtansine vs chemotherapy FDA approved for FR -positive PROC Nov 2022 ADC, antibody-drug conjugate; CI, confidence interval; CT, chemotherapy; FR , folate receptor alpha; mDoR, duration of

response; MIRV, mirvetuximab soravtansine; mo, months; mOS, median overall survival; mPFS, median progression-free survival; ORR, overall response rate; PROC, platinum-resistant ovarian cancer. Full citations for footnotes 56-59 are provided in the

References slide. mPFS: 5.6 vs 4.0 months mOS: 16.5 vs 12.8 months ORR: 42.3% vs 15.9% mDoR: 6.8 vs 4.5 months

ADCs and Chemotherapy have some

Overlapping and Distinct Toxicities Hematologic: anemia, neutropenia, thrombocytopenia Peripheral neuropathy Pneumonitis Cardiac Hepatic Renal GI: nausea, abdominal pain, diarrhea, vomiting, constipation Skin reactions Fatigue Alopecia Chemotherapy

and ADCs60-66 ADCs: Designed to be more targeted, leading to fewer and less severe side effects; however, they can still cause significant toxicity Increased risk of infection Mouth sores, dry mouth Incontinence Cognitive impairment Edema

Dyspnea Chemotherapy62-66 Interstitial lung disease Ocular (vision impairment, keratopathy, dry eye, conjunctivitis) Vascular leak syndrome Immune responses ADCs60-62 Some events, such as ocular events or pneumonitis, can be more severe

or more difficult to manage ADC, antibody drug conjugate; GI, gastrointestinal. Full citations for footnotes 60-66 are provided in the References slide.

Ovarian Cancer Treatment Landscape

has Evolved to be More Molecularly Focused Over the Years aCyclophosphamide, melphalan, cisplatin, etoposide (oral), carboplatin, altretamine, paclitaxel, docetaxel, topotecan, pegylated liposomal doxorubicin (PLD), gemcitabine + carboplatin; bPlus

weekly paclitaxel, PLD or topotecan; cPlus paclitaxel/carboplatin; gemcitabine/carboplatin; dPlus paclitaxel/carboplatin; eNiraparib, rucaparib, and olaparib have been withdrawn as maintenance therapy for platinum-sensitive recurrent BRCAwt ovarian

cancer. 1L, first-line; Ab, antibody; ADC, antibody-drug conjugate; BRCAm, BRCA mutation; dMMR, deficient mis-match repair; FR , folate receptor alpha; HER2, human epidermal growth factor receptor 2; HRD, homologous recombination deficiency;

MSI-H, microsatellite instability - high; PARPi, PARP inhibitor; PD-L1, programmed death receptor - ligand 1; PLD, pegylated liposomal doxorubicin; PROC, platinum-resistant ovarian cancer; PSOC, platinum-sensitive ovarian cancer; SGRM,

selective glucocorticoid receptor modulator; T-DXD, trastuzumab deruxtecan; TMB-H, tumor mutational burden - high; VEGF, vascular endothelial growth factor. Full citations for footnotes 67,68 are provided in the References slide. 1959-2006

2016 2020 2024 2014 2017 2018 2022 Bevacizumabb PROC Chemotherapiesa Bevacizumabc PSOC Niraparib 1L HRD+e Rucaparib 1L BRCA+ e Mirvetuximab soravtansine FR + PROC T-DXD previously treated HER2+ Pembrolizumab Unresectable/ metastatic TMB-H

Bevacizumabd 1L Olaparib 1L BRCA+ e Pembrolizumab Recurrent MSI-H/dMMR M M M Olaparib + bevacizumab 1L HRD+ M FDA approved agents67,68 Anti-VEGF Ab PARPie Anti-PD-L1 Ab ADC Maintenance setting only

The Unmet Medical Need is High for

PROC Despite advances in therapeutic options there is still an unmet need in advanced ovarian cancer, particularly in PROC There is a lack of effective and durable treatment options, leading to poor prognosis and limited survival outcomes Patients